ICML 2023 | Brentuximab vedotin: current status and future considerations for this agent in HL treatment
Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MI, discusses the current use of brentuximab vedotin (BV) in the treatment of Hodgkin lymphoma (HL), and further explains how this may change in the future. Prof. Ansell highlights a recent study which demonstrated a progression-free survival (PFS) benefit in patients treated with nivolumab + doxorubicin, vinblastine, and dacarbazine (AVD), which may further impact the role of BV in the HL treatment landscape. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
Brentuximab vedotin has kind of been a standard agent, which we’ve utilized many times in relapsed patients with Hodgkin lymphoma. Initially the studies were utilized post-transplant, subsequently being used in combinations pre-transplant and then finally being used upfront with AVD chemotherapy compared to the standard ABVD chemotherapy. And the most recent data showed that not only was there an improvement in progression-free survival, there was actually an improvement in overall survival when that was done...
Brentuximab vedotin has kind of been a standard agent, which we’ve utilized many times in relapsed patients with Hodgkin lymphoma. Initially the studies were utilized post-transplant, subsequently being used in combinations pre-transplant and then finally being used upfront with AVD chemotherapy compared to the standard ABVD chemotherapy. And the most recent data showed that not only was there an improvement in progression-free survival, there was actually an improvement in overall survival when that was done. I think that landscape is rapidly changing. So I think it’s a space that we really need to watch. Some data presented at ASCO and also in the plenary here at ICML showed that nivolumab plus AVD chemotherapy improves the progression-free survival at one year compared to brentuximab vedotin-AVD chemotherapy. More follow up is clearly needed, but I think it’s the duel of the new agents, if you like, in other words, competing against each other to see if there’s a better outcome.
Read more...
